Answers are grounded in this paper and cite their sources.
Spinal cord injury (SCI) is characterized by interconnected inflammation, oxidative stress, vascular dysfunction, and impaired neural regeneration, while insufficient lesion-directed delivery further limits the efficacy of systemic therapy. Here, we developed macrophage membrane-camoufl11aged Sr-PDA/Fasudil/MnO2 nanoparticles (MM-NPs) that were designed to integrate inflammation-targeted delivery with complementary immunomodulatory, redox-regulating, and repair-supporting functions. Macrophage membrane camouflage reduced nonspecific phagocytic uptake, enhanced recognition of inflammatory endothelium, improved delivery in an in vitro endothelial barrier model, and increased lesion accumulation in vivo. The formulation provided sustained fasudil release and was designed to combine Rho-associated protein kinase (ROCK) inhibition with redox regulation and bioactive support. MM-NPs consequently attenuated microglial inflammatory activation and excessive reactive oxygen species (ROS) accumulation, improved endothelial migration and angiogenic responses, and alleviated inflammation-induced impairment of neural stem cell differentiation. In a rat SCI model, MM-NPs reduced lesion cavitation and fibrosis, improved the inflammatory microenvironment, enhanced vascular, axonal, and myelin-associated repair, and promoted neurological recovery. Transcriptomic profiling and quantitative spinal cord immunoblotting supported treatment-associated changes in ROCK-associated and NF-κB-related inflammatory signaling. Collectively, MM-NPs couple inflammation-targeted delivery with coordinated immune, redox, vascular, and neural regulation, providing a microenvironment-centered strategy for neurovascular repair after SCI.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: